Yahoo India Web Search

Search results

  1. Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...

  2. www.biogen.com › companyCompany | Biogen

    Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...

  3. en.wikipedia.org › wiki › BiogenBiogen - Wikipedia

    Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan ...

  4. lis.biogenelabsindia.combiogene › designLIS - BIOGENE LABS

    BIOGENE LABS INDIA PVT LTD , Acct No. 920020055428454 - Axis Bank, Sainikpuri Branch, Hyderabad. IFSC Code : UTIB0003175 , Branch Code : 3175.

  5. Jan 31, 2024 · Biogen will focus on LEQEMBI® (lecanemab-irmb) with Eisai and advancing potential new modalities to address the multiple pathologies of the disease and unmet patient needs. A plan for patients participating in clinical trials or on commercially available treatment is in place.

  6. www.linkedin.com › company › biogen-Biogen | LinkedIn

    Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our ...

  7. May 22, 2024 · Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences. May 22, 2024. PDF Version. Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseases.

  1. People also search for